Department of Neurology, Yonsei University College of Medicine, Seoul, Korea.
Department of Radiology, Yonsei University College of Medicine, Seoul, Korea.
JAMA. 2023 Sep 5;330(9):832-842. doi: 10.1001/jama.2023.14590.
Optimal blood pressure (BP) control after successful reperfusion with endovascular thrombectomy (EVT) for patients with acute ischemic stroke is unclear.
To determine whether intensive BP management during the first 24 hours after successful reperfusion leads to better clinical outcomes than conventional BP management in patients who underwent EVT.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, open-label trial with a blinded end-point evaluation, conducted across 19 stroke centers in South Korea from June 2020 to November 2022 (final follow-up, March 8, 2023). It included 306 patients with large vessel occlusion acute ischemic stroke treated with EVT and with a modified Thrombolysis in Cerebral Infarction score of 2b or greater (partial or complete reperfusion).
Participants were randomly assigned to receive intensive BP management (systolic BP target <140 mm Hg; n = 155) or conventional management (systolic BP target 140-180 mm Hg; n = 150) for 24 hours after enrollment.
The primary outcome was functional independence at 3 months (modified Rankin Scale score of 0-2). The primary safety outcomes were symptomatic intracerebral hemorrhage within 36 hours and death related to the index stroke within 3 months.
The trial was terminated early based on the recommendation of the data and safety monitoring board, which noted safety concerns. Among 306 randomized patients, 305 were confirmed eligible and 302 (99.0%) completed the trial (mean age, 73.0 years; 122 women [40.4%]). The intensive management group had a lower proportion achieving functional independence (39.4%) than the conventional management group (54.4%), with a significant risk difference (-15.1% [95% CI, -26.2% to -3.9%]) and adjusted odds ratio (0.56 [95% CI, 0.33-0.96]; P = .03). Rates of symptomatic intracerebral hemorrhage were 9.0% in the intensive group and 8.1% in the conventional group (risk difference, 1.0% [95% CI, -5.3% to 7.3%]; adjusted odds ratio, 1.10 [95% CI, 0.48-2.53]; P = .82). Death related to the index stroke within 3 months occurred in 7.7% of the intensive group and 5.4% of the conventional group (risk difference, 2.3% [95% CI, -3.3% to 7.9%]; adjusted odds ratio, 1.73 [95% CI, 0.61-4.92]; P = .31).
Among patients who achieved successful reperfusion with EVT for acute ischemic stroke with large vessel occlusion, intensive BP management for 24 hours led to a lower likelihood of functional independence at 3 months compared with conventional BP management. These results suggest that intensive BP management should be avoided after successful EVT in acute ischemic stroke.
ClinicalTrials.gov Identifier: NCT04205305.
对于接受血管内血栓切除术 (EVT) 成功再灌注的急性缺血性脑卒中患者,最佳血压 (BP) 控制尚不清楚。
确定在 EVT 后 24 小时内进行强化 BP 管理是否比常规 BP 管理更能改善接受 EVT 治疗的患者的临床结局。
设计、地点和参与者:这是一项多中心、随机、开放标签试验,具有盲终点评估,在韩国的 19 个卒中中心进行,时间为 2020 年 6 月至 2022 年 11 月(最终随访时间为 2023 年 3 月 8 日)。共纳入 306 名接受 EVT 治疗且改良脑梗死溶栓评分 2b 或更高(部分或完全再灌注)的大血管闭塞性急性缺血性脑卒中患者。
参与者被随机分配接受强化 BP 管理(收缩压目标 <140mmHg;n=155)或常规管理(收缩压目标 140-180mmHg;n=150),持续 24 小时。
主要结局为 3 个月时的功能独立性(改良 Rankin 量表评分为 0-2)。主要安全性结局为 36 小时内症状性颅内出血和 3 个月内与指数卒中相关的死亡。
根据数据和安全监测委员会的建议,该试验提前终止,该委员会注意到安全性问题。在 306 名随机患者中,305 名患者被确认为符合条件,302 名(99.0%)完成了试验(平均年龄 73.0 岁;122 名女性[40.4%])。强化管理组达到功能独立性的比例(39.4%)低于常规管理组(54.4%),差异有统计学意义(-15.1%[95%CI,-26.2%至-3.9%]),调整后的优势比(0.56[95%CI,0.33-0.96];P=0.03)。强化组症状性颅内出血发生率为 9.0%,常规组为 8.1%(差异为 1.0%[95%CI,-5.3%至 7.3%]),调整后的优势比为 1.10[95%CI,0.48-2.53];P=0.82)。强化组 3 个月内与指数卒中相关的死亡发生率为 7.7%,常规组为 5.4%(差异为 2.3%[95%CI,-3.3%至 7.9%]),调整后的优势比为 1.73[95%CI,0.61-4.92];P=0.31)。
在接受 EVT 成功再灌注的大血管闭塞性急性缺血性脑卒中患者中,与常规 BP 管理相比,强化 BP 管理 24 小时导致 3 个月时功能独立性的可能性降低。这些结果表明,在急性缺血性脑卒中 EVT 后应避免强化 BP 管理。
ClinicalTrials.gov 标识符:NCT04205305。